2018. október 30., kedd 09:25 |
Grünenthal agrees US$ 922 m deal with AstraZeneca for Nexium and Vimovo (part 1) |
|
Aachen, Germany, 30 October, 2018 (APA/OTS) - Biggest single investment in Grünenthal's history that will significantly strengthen the company's leading position in pain management - Gastroprotective therapies to address a high unmet medical need[1] in pain patients on non-steroidal anti-inflammatory drugs (NSAIDs) - Grünenthal today announced that it has agreed to acquire AstraZeneca's European rights to Nexium and the global (ex US and Japan) rights to Vimovo for a total consideration of up to US$ 922 m (€ 811 m). Nexium (esomeprazole) is a proton pump inhibitor (PPI) that helps to reduce the amount of acid produced by the stomach in patients with gastroesophageal reflux conditions and ulcers. It has a number of indications, including the prevention and treatment of gastric ulcers induced by pain-relieving non-steroidal anti-inflammatory drugs (NSAIDs). Vimovo is a fixed-dose combination tablet of naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID) and esomeprazole, the same gastroprotective active ingredient as in Nexium. It is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk of developing NSAID-associated gastric and/or duodenal ulcers. |
"This acquisition is the biggest single investment in Grünenthal's
history and an important step in pursuing our vision of creating a
world free of pain for patients," explained Grünenthal CEO Gabriel
Baertschi. "There is a high unmet medical need[1] for patients on
long-term high-dose NSAIDs. Despite all guidelines recommending
gastrointestinal protection for these patients, evidence suggests
that many remain unprotected and 1 out of 4 may develop stomach
ulcer with its serious health complications[2]. Therefore, combining
Grünenthal's extensive pain expertise with the well-established
products Nexium and Vimovo is a perfect strategic fit." Grünenthal
is a worldwide leader in innovative pain management and related
therapies.
Under the terms of the agreement, Grünenthal will acquire the
exclusive rights to market Nexium for the approved indications in 33
European countries. Nexium continues to generate significant
revenues despite having lost exclusivity. Total prescription Nexium
2017 sales for in-scope markets were US$ 248 m (€ 220 m). Grünenthal
will obtain Vimovo global commercialization rights with the
exception of the US and Japan. Vimovo is available in over 30
countries and is patent protected in most European markets until
2025. Vimovo achieved revenues of US$ 79 m (€ 70 m) in in-scope
markets in 2017.
With this acquisition Grünenthal is expected to double its EBITDA
performance. Moreover, Grünenthal will significantly enhance its
business across multiple pain related therapeutic categories and
geographies. The transaction is subject to approval from the
relevant antitrust authorities, with closing expected in December
2018. The financing for Grünenthal has been secured by the underwriting
banks BBVA, BNP Paribas, Commerzbank and ING.
About Nexium Nexium (esomeprazole) is used to treat gastroesophageal reflux
disease, ulcers, and Zollinger-Ellison syndrome. It is also used for
the prevention and treatment of gastric ulcers induced by
pain-relieving non-steroidal anti-inflammatory drugs (NSAIDs). It is
a member of the drug class of proton pump inhibitors (PPIs), which
reduce the production of stomach acid. It works by binding to and
inhibiting the acid pumps of a particular type of cells lining the
stomach wall to reduce the production of stomach acid. In doing so,
it lowers the level of acidity in the stomach and helps to heal
erosions in the esophagus or ulcers in the stomach and duodenum.
Nexium is available in several formulations: Nexium gastro-resistant
granules for oral suspension, Nexium gastro-resistant Multi-Unit
Pellet System (Nexium MUPS™) tablets, and Nexium injection/infusion
with varying approved indications. Please consult your local label
for specific approved uses in adults and children.
About Vimovo Vimovo (naproxen/esomeprazole) modified-release tablet is a
fixed-dose combination of naproxen, a pain-relieving non-steroidal
anti-inflammatory drug (NSAID) and esomeprazole, the same
gastroprotective active ingredient as in Nexium. It is indicated for
the symptomatic treatment of osteoarthritis, rheumatoid arthritis
and ankylosing spondylitis in patients who are at risk of developing
NSAID-associated gastric ulcers and/or duodenal ulcers and where
treatment with lower doses of naproxen or of other NSAIDs is not
considered sufficient. The fixed dose combination reduces the
incidence of gastric ulcers by up to 70% compared to Naproxen
alone[3] and therefore provides patients the benefit of both
effective pain relief and adequate gastroprotection. Please consult
your local label for specific approved uses.
About Grünenthal Grünenthal is an entrepreneurial, science-based pharmaceutical
company specialized in pain, gout and inflammation. Our ambition is
to deliver four to five new products to patients in diseases with
high unmet medical need by 2022 and become a € 2 bn company. We are
a fully integrated research & development company with a long track
record of bringing innovative pain treatments and state-of-the-art
technologies to patients. By sustainably investing in our R&D above
the industrial average, we are strongly committed to innovation. Grünenthal is an independent, family-owned company headquartered in
Aachen, Germany. We are present in approx. 30 countries with
affiliates in Europe, Latin America and the US. Our products are
sold in more than 100 countries and approx. 5,200 employees are
working for Grünenthal worldwide. In 2017, Grünenthal achieved
revenues of approx. € 1.3 bn. More information: www.grunenthal.com (continues)
|
|
|
|
|
|
|
2018. október 30., kedd 09:25 |
Grünenthal agrees US$ 922 m deal with AstraZeneca for Nexium and Vimovo (part 2) |
|
Aachen, Germany, 30 October, 2018 (APA/OTS) - |
Follow us on: LinkedIn: Grunenthal Group Twitter: @grunenthalgroup Instagram: gruenenthal
For further information, please contact: Štěpán Kráčala, Head Global Communications Tel.: +49 241 569-1335, Stepan.Kracala@grunenthal.com Grünenthal GmbH, 52099 Aachen, Germany
Kerstin Nacken, Head Editorial Management and Media Relations Tel.: +49 241 569-2710, Kerstin.Nacken@grunenthal.com Grünenthal GmbH, 52099 Aachen, Germany
# # #
1. Scheiman, J.M., Unmet needs in non-steroidal anti-inflammatory
drug-induced upper gastrointestinal diseases. Drugs, 2006. 66 Suppl
1: p. 15-21; discussion 29-33. 2. Lanza, F.L., F.K. Chan, and E.M. Quigley, Guidelines for
prevention of NSAID-related ulcer complications. Am J Gastroenterol,
2009. 104(3): p. 728-38. 3. Angiolillo, D.J., et al., Impact of concomitant low-dose aspirin
on the safety and tolerability of naproxen and esomeprazole
magnesium delayed-release tablets in patients requiring chronic
nonsteroidal anti-inflammatory drug therapy: an analysis from 5
Phase III studies. J Thromb Thrombolysis, 2014. 38(1): p. 11-23.
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
Forrás: OTS Üzleti Sajtószolgálat
MTI © Minden jog fenntartva.
|